Ipratropium bromide

Thymolphthalein.

Thymolphthalein.

Tipelukast (KCA 757) is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.In VitroTipelukast inhibits the binding of [ 3 H] LTD4 to the LTD4 receptors on pul-monary

Tipelukast (KCA 757) is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.In VitroTipelukast inhibits the binding of [ 3 H] LTD4 to the LTD4 receptors on pul-monary

A selective inhibitor of IKK2 (IC₅₀s = 17.9 nM and 0.

A selective inhibitor of IKK2 (IC₅₀s = 17.9 nM and 0.

A selective inhibitor of IKK2 (IC₅₀s = 17.9 nM and 0.

InformationUmeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).TargetsmAChRIn vitroUmeclidinium is a novel mAChR antagonist. The affinity (Ki) of

InformationUmeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).TargetsmAChRIn vitroUmeclidinium is a novel mAChR antagonist. The affinity (Ki) of

InformationUmeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).TargetsmAChRIn vitroUmeclidinium is a novel mAChR antagonist. The affinity (Ki) of

InformationUmeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).TargetsmAChRIn vitroUmeclidinium is a novel mAChR antagonist. The affinity (Ki) of

InformationUmeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).TargetsmAChRIn vitroUmeclidinium is a novel mAChR antagonist. The affinity (Ki) of